http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0515140-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a717ea5b2ac78ac329ab3a9659d834d2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-18 |
| filingDate | 1992-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9c4bf023c9477da58e3839eb40945b5 |
| publicationDate | 1992-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0515140-A1 |
| titleOfInvention | Amide esters of rapamycin |
| abstract | The invention concerns a compound of the structuren n wherein R¹ and R² are each independently, hydrogen orn n X is -(CH₂) m - or -Ar¹- ; R³ and R⁴ are each, independently, hydrogen, alkyl, -(CH₂) n -Ar, -(CH₂) p -NR⁵R⁶, or -(CH₂) p -N⁺R⁵R⁶R⁷Y⁻ ; R⁵ and R⁶ are each, independently, hydrogen, alkyl, or -(CH₂) n -Ar; Ar- and -Ar¹- are each optionally substituted mono- or bivalent radicals respectively of groups selected fromn n n in which the optional substituents are selected from the group consisting of alkyl, aralkyl, alkoxy, cyano, halo, nitro, carbalkoxy, or perfluoroalkyl; R⁷ is alkyl; Y is a halide, sulfate, phosphate, or p-toluenesulfonate anion; m = 1 -6; n = 1-6; p = 1 -6; with the proviso that R¹ and R² are not both hydrogen; or a pharmaceutically acceptable salt thereof, which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases and diseases of inflammation; by virtue of its antitumor activity is useful in treating solid tumors; and by virtue of its antifungal activity is useful in treating fungal infections. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9514023-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5672605-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5583139-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5527907-A |
| priorityDate | 1991-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 175.